| Literature DB >> 24628878 |
Man Chun John Ma, Santosh S Atanur, Timothy J Aitman, Anne E Kwitek1.
Abstract
BACKGROUND: The metabolic syndrome (MetS), a complex disorder involving hypertension, obesity, dyslipidemia and insulin resistance, is a major risk factor for heart disease, stroke, and diabetes. The Lyon Hypertensive (LH), Lyon Normotensive (LN) and Lyon Low-pressure (LL) rats are inbred strains simultaneously derived from a common outbred Sprague Dawley colony by selection for high, normal, and low blood pressure, respectively. Further studies found that LH is a MetS susceptible strain, while LN is resistant and LL has an intermediate phenotype. Whole genome sequencing determined that, while the strains are phenotypically divergent, they are nearly 98% similar at the nucleotide level. Using the sequence of the three strains, we applied an approach that harnesses the distribution of Observed Strain Differences (OSD), or nucleotide diversity, to distinguish genomic regions of identity-by-descent (IBD) from those with divergent ancestry between the three strains. This information was then used to fine-map QTL identified in a cross between LH and LN rats in order to identify candidate genes causing the phenotypes.Entities:
Mesh:
Year: 2014 PMID: 24628878 PMCID: PMC4003853 DOI: 10.1186/1471-2164-15-197
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Distributions of Observed Strain Difference (OSD) over 100Kb windows. OSD distribution is represented as the curve of kernel density estimates (Y axis) against OSD (X axis). The scale of the Y-axis is square-root transformed. The Polymorphism Enrichment Thresholds (PET) for each comparison is marked with a vertical line.
Summary Statistics for OSD analyses for six strain comparisons
| Comparison | PET | # Windows > PET | % Windows > PET | # divergent haplotype blocks | Average block length | SD block length | Average OSD first peak | Average OSD second peak | # SNPs in comparison | # SNPs in haplotype blocks | % SNPs in haplotype blocks |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| LH/BN | 4.50x10−4 | 18,242 | 67.07 | 1,431 | 1,431,996 | 1,506,679 | 5.44x10−5 | 1.69x10−3 | 3,127,650 | 3,078,898 | 98.44 |
| LL/BN | 4.52x10−4 | 17,989 | 66.14 | 1,396 | 1,287,865 | 1,565,760 | 5.10x10−5 | 1.69x10−3 | 3,094,251 | 3,047,301 | 98.48 |
| LN/BN | 4.57x10−4 | 17,982 | 66.11 | 1,398 | 1,285,500 | 1,493,916 | 5.05x10−5 | 1.69x10−3 | 3,082,757 | 3,036,234 | 98.49 |
| Average | 4.53x10−4 | 18,071 | 66.44 | 1,408 | 1,335,120 | 1,522,118 | 5.20x10−5 | 1.69x10−3 | 3,101,553 | 3,054,144 | 98.47 |
|
| |||||||||||
| LH/LN | 3.69x10−4 | 4,202 | 15.45 | 477 | 880,419 | 960,896 | 5.28x10−6 | 1.50x10−3 | 643,234 | 630,814 | 98.07 |
| LH/LL | 3.84x10−4 | 4,041 | 14.86 | 485 | 828,584 | 851,988 | 5.68x10−6 | 1.56x10−3 | 643,233 | 630,878 | 98.08 |
| LL/LN | 3.44x10−4 | 3,510 | 12.90 | 360 | 968,953 | 1,048,667 | 3.74x10−6 | 1.49x10−3 | 532,429 | 531,904 | 99.90 |
| Average | 3.66x10−4 | 3,918 | 14.40 | 441 | 892,652 | 953,850 | 4.90x10−6 | 1.52x10−3 | 606,299 | 597,865 | 98.68 |
Figure 2Patterns of OSD Distribution over 100Kb across the genome in the LH/LN comparison. The scale of the Y-axis is square-root transformed.
Figure 3The overlap between previously reported QTLs and the divergent haplotype blocks between LH and LN. (A): Genome-wide comparison; (B): A focus on the chromosomes 1, 2, 3, 5, 7, 10, 13 and 17 that contains at least one QTL identified by Bilusic et al. In both figures red marks QTL intervals identified by Bilusic et al. and blue marks intervals containing divergent haplotype blocks. Idiograms were drawn using Idiographica [21].
Figure 4Divergent haplotype blocks of different comparisons on RNO17. From top: LH/BN, LL/BN, LN/BN, LH/LL, LH/LN and LL/LN. At the bottom the LH/LN haplotype blocks identified by SNP genotyping was added as reference.
Divergent haplotype blocks between LH and LN strains identified by OSD analysis and SNP genotyping data
| Haplotype blocks OSD analysis | Haplotype blocks STAR genotyping | ||||
|---|---|---|---|---|---|
| Block number | Start (mb) | End (mb) | Length (mb) | Start (mb) | End (mb) |
| 1 | 29.7 | 30.0 | 0.3 | 29.7 | 30.2 |
| 2 | 30.1 | 30.3 | 0.2 | ||
| 3 | 30.7 | 30.9 | 0.2 |
| |
| 4 | 39.4 | 39.6 | 0.2 | 38.2 | 39.8 |
| 5 | 41.7 | 43.1 | 1.4 | 42.2 | 43.2 |
| 6 | 43.2 | 43.4 | 0.2 | ||
| 7 | 53.4 | 53.8 | 0.4 |
| |
| 8 | 62.2 | 63.2 | 1.0 | 62.3 | 65.8 |
| 9 | 63.4 | 64.9 | 1.5 | ||
| 10 | 65 | 65.9 | 0.9 | ||
| 11 | 69.7 | 69.9 | 0.2 | 69.7 | 70.8 |
| 12 | 70.4 | 70.8 | 0.4 | ||
| 13 | 83.6 | 83.9 | 0.3 |
| |
| 14 | 90.8 | 91.1 | 0.3 | 90.8 | 90.9 |
All genome position coordinates are based on the rn4 assembly.
Genes and non-synonymous variations in LH vs LN haplotype blocks on RNO17
| Gene name | Gene start (bp) | Gene end (bp) | Description | Nucleotide Substitution | AA Substitution | Variant strain | Classification |
|---|---|---|---|---|---|---|---|
|
| |||||||
|
| 29,701,923 | 29,708,044 | Transmembrane protein 14C | ||||
|
| 29,710,407 | 29,721,477 | PAK1 interacting protein 1 | ||||
|
| 29,733,271 | 29,746,769 | Similar to chromosome 6 open reading frame 52 |
| V36I | LH | Benign |
|
| R135H | Benign | |||||
|
| C139Y | Benign | |||||
|
| 29,767,388 | 29,872,873 | N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase | C29,872,483 T | A131T | LN | Benign |
|
| |||||||
|
| 30,267,398 | 30,267,637 | CDC28 protein kinase regulatory subunit 2 | G30,267,440A | E15K | LN | Benign |
| T30,267,495C | L33P | Benign | |||||
| G30,267,526C | W43C | Benign | |||||
| G30,267,578 T | E61* | N/A | |||||
|
| |||||||
|
| 42,228,845 | 42,229,431 | Similar to 60S ribosomal protein L29 (P23) | g.42299020_42299027delACTCCGGT | LH | Essential splice site | |
| g.42299028_42299029insCACAAAGATA | X29fs | LN | Frameshift | ||||
|
| 42,984,939 | 42,991,275 | Prolactin family 5, subfamily a, member 2 | G42,989,474A | P14L | LH | Benign |
| A42,986,191 T | LH | Splice site | |||||
|
| |||||||
|
| 43,119,152 | 43,126,570 | Prolactin-5A1 | ||||
|
| 43,276,214 | 43,284,152 | Prolactin-4A1 |
| T141N | LH | Splice site, possibly damaging |
|
| |||||||
|
| 53,402,078 | 53,436,081 | MLN64 N-terminal domain homolog | ||||
|
| 53,441,303 | 53,484,317 | Uncharacterized protein | G53,441,394A | T161I /T313I* | LH | Benign |
| C53,463,467 T | V124I | LH | |||||
| g.53483901_53483997del | 73_105del | LN | Frameshift | ||||
|
| 53,496,423 | 53,528,130 | Uncharacterized protein |
| P81T | LH | Possibly damaging |
|
| T57S | LH | Benign | ||||
|
| P15S | LH | Probably damaging | ||||
|
| A8D | LH | Possibly damaging | ||||
|
| 53,558,804 | 53,802,936 | Amphiphysin | C53,558,811A | R632L | LH | Benign |
| g.53641892_53641893delCT | c.152_153delAG | LN | |||||
|
| 53,773,036 | 53,773,733 | Uncharacterized protein | ||||
|
| |||||||
|
| 62,654,080 | 62,658,885 | BMP and activin membrane-bound inhibitor homolog | ||||
|
| 62,684,244 | 62,686,747 | Uncharacterized protein | ||||
|
| 62,701,289 | 62,741,344 | Cullin-2 | ||||
|
| 62,770,633 | 62,837,668 | cAMP-responsive element modulator | ||||
|
| 63,041,415 | 63,104,046 | Enhancer of polycomb homolog 1 | A63,102,600 T | L55H | LH | Benign |
|
| |||||||
|
| 63,497,924 | 63,529,227 | Ras-related protein Rab-18 | A63,528,108 T | S193C | LN | Benign |
|
| 63,631,426 | 63,710,099 | Mohawk Homeobox | G63,631,814A | P301L | LH | Benign |
|
| 63,931,393 | 63,955,410 | Armadillo repeat containing 4 | ||||
|
| 63,992,387 | 64,282,554 | MAGUK p55 subfamily member 7 | ||||
|
| 64,531,772 | 64,587,027 | WW domain containing adaptor with coiled-coil | T64,570,567G | C200G | LH | Benign |
|
| |||||||
|
| 65,681,793 | 65,702,382 | similar to NSFL1 (p97) cofactor (p47) |
| G80C | LH | Possibly damaging |
|
| |||||||
|
| 83,837,499 | 83,861,361 | Uncharacterized protein | C83,860,804 T | P40S | LH | Benign |
| g.83861107_83861122delATCCCTGCATCCCTGC | I141fs | LN | Frameshift | ||||
| g.83861220_83861227delCCCTGCAT | T178fs | LH | Frameshift | ||||
|
| LH | Splice site | |||||
|
| |||||||
|
| 90,572,391 | 90,982,073 | Plexin domain-containing protein 2 | ||||
Variants in bold were validated by Sanger sequencing.